Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Double-Blinded, Placebo-Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Safety and Pharmacokinetics Trial of AVR-48

NCT06847698 is registered in ClinicalTrials.gov with AyuVis Research, Inc. as lead sponsor.

NCT NCT06847698
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06847698 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Double-Blinded, Placebo-Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Safety and Pharmacokinetics Trial of AVR-48
Lead sponsor
AyuVis Research, Inc.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
June 30, 2025
Completion date
November 30, 2025
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pharmacodynamics, pharmacokinetics, safety issues, tolerability